BioCentury | Feb 29, 2016
Clinical News

AMG 319: Phase II started

...London, U.K.) began a double-blind, placebo-controlled, U.K. Phase II trial to evaluate 400 mg oral AMG 319...
...and Cancer Research Technology (CRT) Ltd. commercial subsidiary. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: AMG 319...
BioCentury | Jun 26, 2014
Targets & Mechanisms

PI3K inhibition: solid immunotherapy

...PI3Kd inhibitor Phase I/II for CLL, B cell lymphoma and hematological malignancies Amgen Inc. (NASDAQ:AMGN) AMG 319...
BioCentury | Sep 6, 2012
Distillery Therapeutics

Indication: Inflammation

...undisclosed but could include evaluating the lead dual inhibitor in additional animal models of inflammation. AMG 319...
BioCentury | May 24, 2012
Targets & Mechanisms

Getting selective for gamma

...1,240 PI3Kd: 70 Chronic lymphocytic leukemia (CLL); non-Hodgkin's lymphoma (NHL) Phase III Amgen Inc. (NASDAQ:AMGN) AMG 319...
BioCentury | Feb 27, 2012
Product Development

Take your PI(3)K

...1,240; delta: 70 Chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL) Ph II Amgen Inc. (NASDAQ:AMGN) AMG 319...
BioCentury | Jan 30, 2012

Amgen swallows BiTEs

...leukemia (ALL). Indeed, the company has only one disclosed clinical program in a hematological cancer. AMG 319...
BioCentury | Oct 13, 2011
Targets & Mechanisms

Getting fat off PI3Kgamma

A team of Swiss researchers has shown that knocking out an isoform of the cancer target phosphoinositide 3-kinase led to weight loss and increased insulin sensitivity in mice. 1 The challenge will be designing compounds...
Items per page:
1 - 7 of 7